Four members now compose the Audit Committee of Coya Therapeutics, Inc. (Nasdaq: COYA) after the board voted August 6, 2026 to seat director Mark H. Pavao as the fourth, per an 8-K/A filed with the Securities and Exchange Commission on August 7. Three seats were already held by Dr. Dov Goldstein, Dr. Ann Lee, and Dieter Weinand before the board acted. The amendment closes a disclosure gap left open since the company's original Form 8-K, dated March 29, 2026 and filed April 2, 2026, which reported Pavao's board election, effective April 1, without assigning him to any committee.
Audit Committee composition, as reported Aug. 6, 2026
| Member | Role |
|---|---|
| Dr. Dov Goldstein | Chair |
| Dr. Ann Lee | Member |
| Dieter Weinand | Member |
| Mark H. Pavao | Member |
The Nominating and Corporate Governance Committee recommended Pavao's placement on the Audit Committee. The board accepted that recommendation with the appointment effective immediately on August 6.
Filing context
The 8-K/A covers Item 5.02 of Form 8-K under the Securities Exchange Act of 1934, addressing director and officer changes. Short disclosure. The original April 2 filing stated explicitly that no committee determination had been made for Pavao at that time. The company characterized the amendment as filed solely to report the Audit Committee appointment; no other disclosures were made.
Arun Swaminathan, CEO, signed the amendment on August 7, 2026. Coya Therapeutics is incorporated in Delaware, listed on the Nasdaq Stock Market under commission file number 001-41583, and holds emerging growth company status under Rule 405 of the Securities Act of 1933. The company is headquartered at 5850 San Felipe St., Suite 500, Houston, Texas 77057. Common stock carries a par value of $0.0001 per share.
Related reading
- Eli Lilly posts $23 billion Q2 as Mounjaro, Zepbound carry GLP-1 lead over Viking Therapeutics
- Sanuwave Health Q2 2026: $9.7M Revenue, Adjusted EBITDA Falls 62% as System Sales Slide
- CVS Health beats estimates, raises guidance on insurance recovery and Eli Lilly collaboration
- CION Investment Corporation shifts capital toward buybacks as repurchase program reaches $130 million